Abstract: A discharge gas manifold having a main conduit, an end feeder conduit, and at least one intermediate feeder conduit, wherein the at least one intermediate feeder conduit contains a portion, adjacent to the main conduit, that forms an angle between 0°-60° with the axis of the main conduit.

Abstract: A discharge gas manifold having a main conduit, an end feeder conduit, and at least one intermediate feeder conduit, wherein the at least one intermediate feeder conduit contains a portion, adjacent to the main conduit, that forms an angle between 0°-60° with the axis of the main conduit.

Abstract: A discharge gas manifold having a main conduit, an end feeder conduit, and at least one intermediate feeder conduit, wherein the at least one intermediate feeder conduit contains a portion, adjacent to the main conduit, that forms an angle between 0°-60° with the axis of the main conduit.

Abstract: A discharge gas manifold having a main conduit, an end feeder conduit, and at least one intermediate feeder conduit, wherein the at least one intermediate feeder conduit contains a portion, adjacent to the main conduit, that forms an angle between 0°-60° with the axis of the main conduit.

Abstract: A genetically disabled mutant virus has a genome which is defective in respect of a selected gene that is essential for the production of infectious new virus particles, and which carries heterologous genetic material encoding an immunomodulatory protein such as GM-CSF, IL-2, or others, such that the mutant virus can infect normal host cells and cause expression of immunomodulatory protein, but the mutant virus cannot cause production of infectious new virus particles except when the virus infects recombinant complementing host cells expressing a gene that provides the function of the essential viral gene; the site of insertion of the heterologous genetic material encoding the immunomodulatory protein preferably being at the site of the defect in the selected essential viral gene. Uses include prophylactic and therapeutic use in generating an immune response in a subject treated therewith; use in the preparation of an immunogen such as a vaccine for use in tumour therapy; use in the in-vitro expansion of (e.

Abstract: A genetically disabled mutant virus has a genome which is defective in respect of a selected gene that is essential for the production of infectious new virus particles, and which carries heterologous genetic material encoding an immunomodulatory protein such as GM-CSF, IL-2, or others, such that the mutant virus can infect normal host cells and cause expression of immunomodulatory protein, but the mutant virus cannot cause production of infectious new virus particles except when the virus infects recombinant complementing host cells expressing a gene that provides the function of the essential viral gene; the site of insertion of the heterologous genetic material encoding the immunomodulatory protein preferably being at the site of the defect in the selected essential viral gene. Uses include prophylactic and therapeutic use in generating an immune response in a subject treated therewith; use in the preparation of an immunogen such as a vaccine for use in tumour therapy; use in the in-vitro expansion of (e.

Abstract: A genetically disabled mutant virus has a genome which is defective in respect of a selected gene that is essential for the production of infectious new virus particles, and which carries heterologous genetic material encoding an immunomodulatory protein such as GM-CSF, IL-2, or others, such that the mutant virus can infect normal host cells and cause expression of immunomodulatory protein, but the mutant virus cannot cause production of infectious new virus particles except when the virus infects recombinant complementing host cells expressing a gene that provides the function of the essential viral gene; the site of insertion of the heterologous genetic material encoding the immunomodulatory protein preferably being at the site of the defect in the selected essential viral gene. Uses include prophylactic and therapeutic use in generating an immune response in a subject treated therewith; use in the preparation of an immunogen such as a vaccine for use in tumor therapy; use in the in-vitro expansion of (e.g.

Abstract: Herpesvirus amplicon preparations comprise an origin of replication, a packaging sequence, and at least one inserted gene under control of a promoter, suitable for use as an immunogen or vaccine, in association with helper herpesvirus or DNA, wherein the associated helper virus is of restricted replication competence in a normal host cell; for example where the associated helper virus has an inactivating defect in respect of a gene essential for production of infectious new virus particles, and where the amplicon carries an inserted gene necessary for the propagation of the helper virus.

Abstract: The invention provides a recombinant virus vector for use as an immunotherapeutic or vaccine. The recombinant virus vector comprises at least one pair of nucleotide sequences heterologous to the virus and which have sufficient sequence homology that recombination between them might be expected. The pair of nucleotide sequences are arranged in the virus vector such that they are inverted with respect to each other. The virus vector is able to infect a mammalian host cell and express as polypeptide the heterologous nucleotide sequences in the host cell. For infection thought to be caused by HPV infection, the pair of nucleotide sequences encode part or all of human papillomavirus (HPV) wild-type proteins or mutant proteins immunologically cross-reactive therewith. For an immunotherapeutic or vaccine against cervical cancer, the recombinant virus vector encodes part or all of the HPV wild-type proteins HPV16E7 and HPV18E7 or mutant proteins immunologically cross-reactive therewith.

Abstract: In an air terminal having an inflatable bellows expanding toward a pair of spaced cut-off plates, a sealing element is attached to the central portion of that side of the bellows adjacent to the cut-off plates. The transversely extending ends of the sealing element are not secured to the bellows but are free to separate therefrom as the bellows is expanded to thereby more easily engage the cut-off plates. A pair of foam strips are provided near the transverse ends of the sealing element so as to thereby provide a substantially normally extending surface against which the flowing air will impinge so as to thereby reduce the sound emanating therefrom. A pair of vibration damper clips extend from the cut-off plates and engage the foam strips to prevent any vibration thereof. Pads are secured to the edges of the cut-off plates so as to engage the seal element then thereby enhancing the sealing relationship between the cut-off plates and the seal element.

Abstract: Low frequency noise and turbulence are reduced in a damper structure by providing a perforate screen extension onto the damper blade so as to extend across the flow path when the damper is open. Additionally, a perforate screen is located immediately downstream of the damper and spaced from the wall so as to define a chamber therewith as well as defining a boundary of the flow path.

Abstract: A spoiler is located on the damper blade of a damper assembly such that it serves to divert the flow from the hinge area to avoid air separation. Further, the spoiler does not define the most restricted portion of the flow path and thereby has a minimal effect on the flow resistance.